DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for spastic diplegia — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSpastic diplegia maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for spastic diplegia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interferon induced with helicase C domain 1 (IFIH1) — IFIH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9LOV · 3.07 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Spastic diplegia is the most common form of cerebral palsy worldwide, but many disorders mimic it, which can lead to misdiagnosis and negative implications for treatment and family counselling. A 2014 review provides a diagnostic algorithm to assist physicians in making the correct diagnosis, but does not report any trial data or outcomes.
A single-blind randomised controlled trial from 2025 examined whole-body vibration (WBV) in 54 children with spastic diplegic cerebral palsy in Saudi Arabia. The WBV group (n=28, mean age 9.47 years) received standard physical therapy plus WBV; the control group (n=26, mean age 9.73 years) received standard physical therapy alone, three times per week for four weeks. After treatment, function, muscle strength, and sensory motor integration showed statistically significant differences favouring the WBV group (p<0.05). However, muscle tone was not substantially improved (p=0.10). Within the control group, spasticity, function, and trace assessment did not improve significantly (p=0.33, 0.06, and 0.54 respectively). The authors conclude that both conventional physical therapy and WBV are beneficial, but the trial was short (four weeks) and the sample size small.
A 1991 report describes MRI findings in 34 children with spastic diplegia examined between 2 and 10 years of age, but provides no treatment outcomes or survival data.
What is still missing are larger, longer-term randomised trials that can stratify patients by severity or MRI findings, and any pharmacological intervention tested specifically for spastic diplegia. No drug therapy is mentioned in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Child Neurology · 2003 · 40 citations
Neurosurgical Treatment of Spasticity and Other Pediatric Movement Disorders
AbstractFor children whose spasticity and movement disorders are inadequately treated by oral medications and botulinum toxins, neurosurgical procedures are now available to effectively treat spasticity, tremor, and many cases of dystonia. Spastic diplegia can be treated with selective lumbar rhizotomies, which significantly decrease spasticity, increase range of motion, and improve Gross Motor Function Measure scores. Children with spastic quadriparesis and those with secondary dystonia can be treated with intrathecal baclofen, which diminishes both spasticity and dystonia and is associated with improved function and quality of life. Children with primary dystonia and those with tremor can be treated with deep brain stimulation of the internal globus pallidus and thalamus, respectively. Some children with chorea respond to deep brain stimulation. There are no effective neurosurgical treatments for athetosis or ataxia. The effectiveness of neurosurgical treatments of pediatric movement disorders has increased significantly in the past 15 years.
Archives of Disease in Childhood · 2014 · 22 citations
The differential diagnosis of spastic diplegia
AbstractSpastic diplegia is the most common form of cerebral palsy worldwide. Many disorders mimic spastic diplegia, which can result in misdiagnosis for the child with resultant negative treatment and family counselling implications. In this paper, the authors provide a brief review of spastic diplegia and the various disorders in the differential diagnosis. We also provide a diagnostic algorithm to assist physicians in making the correct diagnosis.
Journal of Multidisciplinary Healthcare · 2025 · 0 citations · open access
The Impact of Whole Body Vibration on Muscle Tone, and Sensory Motor Function in Children with Spastic Diplegic Cerebral Palsy
AbstractPurpose: Children with diplegic cerebral palsy (CP) have limited muscle tone, function, and sensorimotor function. Whole-body vibration (WBV) has been suggested to enhance muscle tone and function in diplegic CP. However, there were limited studies involving the effect of WBV on the tone and function of diplegic CP; we aimed to investigate the effect of WBV on muscle tone, function, and sensorimotor function in children with CP. Patients and Methods: This is a single-blind randomized controlled clinical trial involving 54 spastic diplegic CP child recruited from local rehabilitation centers in the Ha'il region of Saudi Arabia, they were randomly divided into the WBV group (n = 28 with mean age of 9.47±1.92), which received standard physical therapy and WBV therapy, and the control group (n = 26 with mean age of 9.73±1.62) they received standard physical therapy three time per week for four weeks; Muscle tone, function, strength and Sensory motor integration were evaluated pre and post interventions. Results: At baseline, the two groups had no significant differences. After treatment, the measured outcomes (function, muscle strength, and sensory motor integration) showed statistically significant differences (p < 0.05). However, muscle tone was not substantially improved (p = 0.10). In addition, within-group comparisons demonstrated substantial effects (p < 0.05) except Spasticity, Function, and trace assessment of the control group, where the p-values were(0.33, 0.06, and 0.54, respectively). Conclusions: According to the findings in this study, both conventional physical therapy and WBV are beneficial in treating spastic diplegia.
Galter Health Sciences Library, Northwestern University · 1991 · 0 citations · open access
Spastic Diplegia and the MRI
AbstractThe MRI findings in 34 children with spastic diplegia examined between 2 and 10 years of age are reported from the Seirei-Hamamatsu General Hospital, Mikatabara, Hammamatsu, Shizuoka; Nagoya City Medical School; and the National Rehabilitation Center for Disabled Children, Tokyo, Japan.
AbstractThe MRI findings in 34 children with spastic diplegia examined between 2 and 10 years of age are reported from the Seirei-Hamamatsu General Hospital, Mikatabara, Hammamatsu, Shizuoka; Nagoya City Medical School; and the National Rehabilitation Center for Disabled Children, Tokyo, Japan.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
